...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation
【24h】

Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation

机译:造血干细胞移植后年龄调整的受体移植前端粒长度和与治疗相关的死亡率

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Telomere attrition induces cell senescence and apoptosis. We hypothesized that age-adjusted pretransplantation telomere length might predict treatmentrelated mortality (TRM) after hematopoietic stem cell transplantation (HSCT). Between 2000 and 2005, 178 consecutive patients underwent HSCT from HLAidentical sibling donors after myeloablative conditioning regimens, mainly for hematologic malignancies (n = 153). Blood lymphocytes' telomere length was measured by real-time quantitative PCR before HSCT. Age-adjusted pretransplantation telomere lengths were analyzed for correlation with clinical outcomes. After age adjustment, patients' telomere-length distribution was similar among all 4 quartiles except for disease stage. There was no correlation between telomere length and engraftment, GVHD, or relapse. The overall survival was 62% at 5 years (95% confidence interval [CI], 54-70). After a median follow-up of 51 months (range, 1-121 months), 43 patients died because of TRM. The TRM rate inversely correlated with telomere length. TRM in patients in the first (lowest telomere length) quartile was significantly higher than in patients with longer telomeres (P =.017). In multivariate analysis, recipients' age (hazard ratio, 1.1; 95% CI,.0-1.1; P =.0001) and age-adjusted telomere length (hazard ratio, 0.4; 95% CI; 0.2-0.8; P =.01) were independently associated with TRM. In conclusion, age-adjusted recipients' telomere length is an independent biologic marker of TRM after HSCT.
机译:端粒磨损会诱导细胞衰老和凋亡。我们假设年龄调整后的移植前端粒长度可以预测造血干细胞移植(HSCT)后与治疗相关的死亡率(TRM)。在2000年至2005年之间,采用清髓性调理方案后,连续178例来自HLA相同兄弟姐妹供者的HSCT患者(主要针对血液系统恶性肿瘤)(n = 153)。在HSCT之前,通过实时定量PCR测量血淋巴细胞的端粒长度。分析了年龄调整后的移植前端粒长度与临床结果的相关性。调整年龄后,除疾病阶段外,所有四个四分位数的患者端粒长度分布均相似。端粒长度与植入,GVHD或复发之间无相关性。 5年总生存率为62%(95%置信区间[CI],54-70)。在中位随访51个月(1-121个月)后,有43例患者因TRM死亡。 TRM速率与端粒长度成反比。第一个四分位数(最低端粒长度)患者的TRM显着高于长端粒的患者(P = .017)。在多变量分析中,接受者的年龄(危险比,1.1; 95%CI,.0-1.1; P = .0001)和年龄调整的端粒长度(危险比,0.4; 95%CI; 0.2-0.8; P =。 01)与TRM独立相关。总之,年龄校正后的受体端粒长度是HSCT后TRM的独立生物学标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号